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Background: Poorer virologic response to nevirapine- versus efavirenz-
based antiretroviral therapy (ART) has been reported in adult systematic 
reviews and pediatric studies.
Methods: We compared drug discontinuation and viral load (VL) response 
in ART-naïve Ugandan/Zimbabwean children ≥3 years of age initiating 
ART with clinician-chosen nevirapine versus efavirenz in the ARROW 
trial. Predictors of suppression <80, <400 and <1000 copies/mL at 36, 48 
and 144 weeks were identified using multivariable logistic regression with 
backwards elimination (P = 0.1).
Results: A total of 445 (53%) children received efavirenz and 391 (47%) 
nevirapine. Children receiving efavirenz were older (median age, 8.6 vs. 7.5 
years nevirapine, P < 0.001) and had higher CD4% (12% vs. 10%, P = 0.05), 
but similar pre-ART VL (P = 0.17). The initial non-nucleoside-reverse-
transcriptase-inhibitor (NNRTI) was permanently discontinued for adverse 
events in 7 of 445 (2%) children initiating efavirenz versus 9 of 391 (2%) 
initiating nevirapine (P = 0.46); at switch to second line in 17 versus 23, for 
tuberculosis in 0 versus 26, for pregnancy in 6 versus 0 and for other reasons 
in 15 versus 5. Early (36–48 weeks) virologic suppression <80 copies/mL 
was superior with efavirenz, particularly in children with higher pre-ART VL 
(P = 0.0004); longer-term suppression was superior with nevirapine in older 
children (P = 0.05). Early suppression was poorer in the youngest and old-
est children, regardless of NNRTI (P = 0.02); longer-term suppression was 
poorer in those with higher pre-ART VL regardless of NNRTI (P = 0.05). 
Results were broadly similar for <400 and <1000 copies/mL.
Conclusion: Short-term VL suppression favored efavirenz, but long-term 
relative performance was age dependent, with better suppression in older 
children with nevirapine, supporting World Health Organization recom-
mendation that nevirapine remains an alternative NNRTI.
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Globally, >3 million children/adolescents are living with HIV, >90% in sub-Saharan Africa.1 World Health Organization 
(WHO) guidelines recommend children/adolescents ≥3 years ini-
tiate 2 nucleoside-reverse-transcriptase-inhibitors (NRTI) plus 1 
non-nucleoside-reverse-transcriptase-inhibitor (NNRTI). The pre-
ferred NNRTI is efavirenz (with nevirapine an alternative) based on 
systematic reviews indicating better viral load (VL) response2 and 
short-term toxicity.3 However, pediatric nevirapine-based fixed-
dose combinations are widespread in resource-limited settings4; 
understanding whether nevirapine is associated with poorer viro-
logic response in children initiating antiretroviral therapy (ART) ≥3 
years of age has continuing programmatic relevance.
In adults, a 2010 Cochrane review concluded that nevirapine 
and efavirenz had equivalent efficacy based on 7 randomized con-
trolled trials.5 A separate examination of 5 observational studies in 
low- and middle-income countries generally favored efavirenz; 6 
studies in high-income countries were more heterogeneous. The 
2012 systematic review,2 on which the WHO guidelines were based, 
included 26 trials and 7 observational studies with tenofovir + lami-
vudine or tenofovir + emtricitabine backbones.6 This review, and a 
2013 meta-analysis7 of 10 trials and 28 studies with no 2 NRTI back-
bone restriction, concluded efavirenz had superior efficacy. However, 
a 2012 systematic review8 restricted to 7 trials in resource-limited set-
tings concluded that nevirapine and efavirenz showed similar efficacy.
In children, observational studies have also generally con-
cluded that efavirenz had superior efficacy. In 804 Batswana children 
3–16 years of age initiating ART with nevirapine (median age, 7 years) 
or efavirenz (8 years) (NNRTI chosen by clinician), 101 of 383 (26%) 
receiving nevirapine and 57 of 421 (14%) efavirenz experienced viro-
logic failure [lack of suppression to <400 copies/mL by 6 months or 
confirmed ≥400 copies/mL postsuppression; unadjusted hazard ratio 
(HR) = 2.0 [95% confidence interval (CI): 1.4–2.7] P < 0.001, adjusted 
HR (aHR) reported as similar].9 Thai studies have generally reported 
similar results,10,11 most recently in 201511 where nevirapine was a pre-
dictor for virologic failure (≥1000 copies/mL after ≥24-weeks ART) 
[aHR = 1.63 (1.14–2.32) P = 0.004], although a 2011 study12 reported 
no significant difference [unadjusted HR = 1.46 (0.66–3.22)]. In 675 
children <18 years (84%, ≥3 years) in the United Kingdom/Ireland 
Collaborative HIV Paediatric Study (CHIPS) initiating 2 NRTI plus 
nevirapine (median age, 4 years) or efavirenz (10 years), suppres-
sion <400 copies/mL within 12 months did not significantly differ 
[adjusted rate ratio (efavirenz:nevirapine) = 1.16 (0.95–1.41)] but over 
all follow-up, risk of subsequent virologic failure (confirmed >400 
copies/mL) was lower with efavirenz [adjusted rate ratio = 0.54 (0.40–
0.72)].13 Differences were most pronounced in the first 2 years (interac-
tion P = 0.03). Two cross-sectional Tanzanian studies reported that risk 
of virologic failure was lower with efavirenz.14,15 A study of 250 Ugan-
dan children/adolescents (median age, 9 years, range 0–18) compared 
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efavirenz predominantly with zidovudine + lamivudine versus nevi-
rapine predominantly with stavudine + lamivudine. Twelve-month 
virologic failure was higher in nevirapine [adjusted odds ratio (aOR) 
(nevirapine:efavirenz) = 2.46 (1.23–4.90), P = 0.01].16
Considering toxicity, a meta-analysis found nevirapine had 
more adverse events (AEs) resulting in drug substitution or treat-
ment discontinuation [odds ratio (OR) = 2.2 (1.9–2.6) in adults 
≥15 years; limited data in infants/children with each study report-
ing different outcomes].3 However, with efavirenz, one concern is 
central nervous system (CNS) events, with a risk ratio (vs. nevirap-
ine) of 1.4 (0.75–2.59) in children/adolescents ≥5 years in 1 Ugan-
dan study.17 However, in the recent CHIPS study, discontinuation 
because of toxicity was 27 of 370 (7.3%) with 2 or 3 NRTIs plus 
nevirapine versus 32 of 424 (7.5%) with efavirenz.13
We therefore compared VL response and treatment discon-
tinuation on first-line nevirapine- and efavirenz-based ART initi-
ated in children ≥3 years of age in the ARROW trial.18
MATERIALS AND METHODS
Observational analyses included 836 previously untreated Ugan-
dan/Zimbabwean children initiating efavirenz- or nevirapine-based 
ART, 3–17 years of age in the ARROW trial (ISCRTN24791884).18 
Children were randomized 1:1:1 to open-label lamivudine + abacavir 
+ NNRTI continuously (Arm-A; control, no zidovudine); induction 
maintenance with 4-drug lamivudine + abacavir + NNRTI + zido-
vudine for 36 weeks, then lamivudine + abacavir + NNRTI (Arm-B; 
short-term zidovudine) or lamivudine + abacavir + zidovudine (Arm-
C; long-term zidovudine). The NNRTI (nevirapine/efavirenz) was cho-
sen by clinicians; both were available in all centers throughout the trial 
for initial ART and substitutions. Simultaneously, children were rand-
omized 1:1 in a factorial design to clinically driven monitoring versus 
laboratory plus clinical monitoring for toxicity (hematology/biochem-
istry) and efficacy (CD4). After ≥36 weeks, eligible children taking 
lamivudine + abacavir twice daily were randomized to continue twice 
daily or move to once daily. Children were recruited from 1 Zimba-
bwean (University of Zimbabwe, Harare, Zimbabwe) and 3 Ugandan 
centers (Joint Clinical Research Centre, Kampala, Uganda; Baylor-
Uganda, Mulago, Kampala, Uganda; MRC/UVRI Uganda Research 
Unit on AIDS, Entebbe, Uganda). ARROW was approved by research 
ethics committees in Uganda, Zimbabwe and the United Kingdom. 
Caregivers gave written consent.
Postbaseline VL was assayed retrospectively on stored 
plasma at 4, 24, 36, 48 and 144 weeks in all children <5 years 
at ART initiation. VL was also assayed at these time points and 
24-weekly post-week 48 in a subset of children enrolled post-June 
2008 (immunology substudy); and at, and 48 and 96 weeks after, 
randomization to once- versus twice-daily lamivudine + abacavir 
(shown to be virologically equivalent).19 Assays used Abbott Real-
Time and Roche Amplicor 1.5: because many samples had low vol-
umes and had to be diluted 1:2, the lower limit of detection was 
80 copies/mL. Analysis used closest measurements to nominal 
time points in equally spaced windows [results available for 37% 
(n = 309), 35% (n = 282), 42% (n = 341), 44% (n = 241) and 49% 
(n = 265), respectively, of those alive and in follow-up, broadly sim-
ilar in nevirapine vs. efavirenz]. In 145 Arm-A/B immunology sub-
study children alive and in follow-up at 24 weeks (with complete 
VLs), virologic failure was defined as ≥400 copies/mL at week 24 
or subsequent confirmed ≥400 copies/mL through 3 years.9,13,16
The primary (nonrandomized) exposure was NNRTI received 
at ART initiation (efavirenz vs. nevirapine) using intention-to-treat. 
Child characteristics were compared across these groups using χ2 
(categorical factors) and Wilcoxon (continuous factors) tests. Suppres-
sion <80, <400 and <1000 copies/mL with efavirenz and nevirapine 
was compared using generalized estimating equations for global tests 
over time (binomial distribution, independent working correlation). At 
36-, 48- and 144-weeks post-ART initiation, predictors of suppression 
<80, <400 and <1000 copies/mL were identified using logistic regres-
sion, forcing efavirenz versus nevirapine and age at ART initiation into 
models. Models included children with VL at baseline and the relevant 
time point (92%, 89% and 83% of those with VLs at 36, 48 and 144 
weeks). Other factors considered as potential confounders were pre-
ART WHO stage, CD4%, weight/height-for-age,20 VL, gender, center, 
ART strategy randomization, monitoring randomization, whether the 
caregiver/child reported missed doses in the last 4 weeks and percent-
age of scheduled visits to date with missed doses in the last 4 weeks. 
For each time point, independent predictors of suppression <80 copies/
mL were identified using backward elimination (exit P ≥ 0.1 to 
develop an explanatory models; interactions between variables in final 
models retained where P < 0.1). Additional predictors of suppression 
<400 and <1000 copies/mL were then identified using forward selec-
tion (entry P = 0.1), forcing in factors included in the <80 copies/mL 
model. Factors in any of the models were then included in final time-
point-specific models for each threshold, allowing the impact of the 
same factor to be assessed over the different thresholds. Nonlinearity 
was explored using natural cubic splines21 (knots at 10th, 50th and 90th 
centiles), then represented by categorization. Potential confounders of 
the association between efavirenz/nevirapine and early death (before 
week 36) and permanent discontinuation of initial NNRTI were identi-
fied using logistic [adjusting for CD4% only (low number of events)] 
and Cox regression (backwards elimination), respectively. Analyses 
used Stata 14.1 (StataCorp, College Station, TX). P values are 2 sided.
RESULTS
A total of 836 previously untreated children 3–17 years of 
age initiated ART between March 2007 and October 2008. Of the 
836 children, 445 (53%) received efavirenz and 391 (47%) nevirap-
ine. Children on efavirenz were more likely to be male and WHO 
stage 1/2, were older and less underweight/stunted at ART initiation 
(P < 0.01), but had similar VL (P = 0.17) (Table 1). Reflecting local 
availability, center strongly predicted receiving efavirenz versus 
nevirapine (P < 0.001).
Four of 445 (1%) initiating efavirenz and 18 of 391 (5%) 
initiating nevirapine died before week 36. Although the difference 
persisted after adjusting for CD4% (P = 0.01), causes of death 
were primarily infection related and similar between efavirenz/
nevirapine (septicemia/meningitis 0/7, pneumonia 1/4, chronic 
diarrhea/wasting/hypokalemia 1/3, stroke/cerebrovascular 1/2 and 
uncertain 1/2), with similarly low CD4% [median (interquartile 
range), 8 (5–11) vs. 3 (1–14) respectively]. The initial NNRTI was 
permanently discontinued before week 36 in 8 (2%) initiating efa-
virenz [2 AE, 4 voluntary decision and 2 pregnancy-related] and 
22 (6%) initiating nevirapine (9 AE and 13 tuberculosis treatment) 
(P = 0.001 Cox regression adjusting for age at ART initiation). At 
week 36, those randomized to Arm-C (3 NRTI maintenance) dis-
continued NNRTI [excepting 5/2 previously discontinuing zidovu-
dine (anemia)/abacavir (hypersensitivity), respectively]. Amongst 
children randomized to 2 NRTI + NNRTI maintenance (Arm-A/B), 
13 died after week 36 [6/294 (2%) efavirenz and 7/269 (3%) nevi-
rapine]. After week 36, the initial NNRTI was permanently dis-
continued in 37/294 (13%) initiating efavirenz (5 AE, 17 switch 
to second line, 4 pregnancy related, 1 voluntary decision and 10 
other) and 41/269 (15%) nevirapine (23 switch to second line, 13 
tuberculosis treatment, 1 voluntary decision and 4 other) (Cox P 
= 0.31 unadjusted, 0.009 adjusted for age and CD4% at ART ini-
tiation and center). Overall, Arm-A/B children initiating efavirenz 
or nevirapine spent 94.4% and 88.9% follow-up-time through to 
their last clinic visit (median, 4-years follow-up) on efavirenz- or 
nevirapine-containing ART, respectively.
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Over total follow-up, the initial NNRTI was permanently 
discontinued because of an AE in 7 of 445 (2%) initiating efavirenz 
[3 lipodystrophy (2 Arm-B previously receiving zidovudine), 2 
gynecomastia and 2 hypersensitivity reaction] and 9 of 391 (2%) 
nevirapine (4 hypersensitivity reaction, 1 Stevens-Johnson syn-
drome, 1 rash, 1 acute febrile episode, 1 lactic acidosis and 1 raised 
liver enzymes) (P = 0.46 Fisher exact test). In nevirapine, all 9 AEs 
were <10 weeks post-ART initiation (median, 23 days; interquartile 
range, 15–30) and 8 of 9 substituted with efavirenz; in efavirenz, 2 
were <10 weeks, the remaining 5 were a median 3.3 years (3.2–3.8) 
after ART initiation.
Of the 563 participants, 459 (81.5%) initiating long-term 
NNRTI (Arm-A/B) had ≥1 postbaseline VL. Over all follow-up, 
there was a trend to better suppression <80 copies/mL with efa-
virenz (global unadjusted P = 0.11), driven by effects before 36 
weeks (P = 0.007 ≤36 weeks and P = 0.83 ≥48 weeks). There 
was no evidence of difference for <400 copies/mL (P = 0.57) or 
<1000 copies/mL (P = 0.33), with a difference in <1000 copies/
mL at week 4 only (P = 0.02, ≥24 weeks P = 0.77) (Fig. 1). Mean 
VL reduction from weeks 0–4 was 2.4 log
10
 with efavirenz and 
2.3 log
10
 with nevirapine (P = 0.18, n = 302). At week 36, 160 of 
200 (80.0%) efavirenz versus 93 of 141 (66.0%) nevirapine were 
<80 copies/mL (+14.0% [95% CI: 4.5, 23.6] P = 0.004), com-
pared with 181 (90.5%) versus 122 (86.5%), respectively, <400 
copies/mL (+4.0% [−3.0,10.9] P = 0.25). By week 48, suppres-
sion <80, <400 and <1000 copies/mL was similar for efavirenz 
and nevirapine (P = 0.97, P = 0.78 and P = 0.40, respectively). 
Despite little switching to second-line ART (similar with both 
NNRTIs), suppression remained similar at week 144 (106 of 141 
(75.2%) vs. 89 of 124 (71.8%) <80 copies/mL, 116 (82.3%) vs. 
101 (81.5%) <400 copies/mL and 118 (83.7%) vs. 106 (85.5%) 
<1000 copies/mL; P > 0.5).
However, in adjusted analyses (Table 2), differences in 
suppression between efavirenz versus nevirapine differed by both 
baseline VL and age at ART initiation; and these relationships 
varied over follow-up. At week 36, suppression <80 copies/mL 
did not depend on pre-ART VL in efavirenz, but declined with 
increasing pre-ART VL in nevirapine; the net effect was greater 
suppression with efavirenz in those with pre-ART VL >35,000 
copies/mL (overall effect of efavirenz vs. nevirapine P = 0.0004; 
heterogeneity/interaction P = 0.007) (Table 2; Fig. A, Supplemen-
tal Digital Content 1, http://links.lww.com/INF/C646). Suppres-
sion <400 and <1000 copies/mL was broadly similar (Table, Sup-
plemental Digital Content 2, http://links.lww.com/INF/C647). 
This effect had weakened by week 48 (heterogeneity/interaction 
P = 0.15; Table 2; Fig. B, Supplemental Digital Content 2, http://
links.lww.com/INF/C646), and by week 144, suppression <80 
copies/mL was lower in those with higher pre-ART VL (P = 0.05) 
in both groups (heterogeneity/interaction P = 0.8).
Considering age at ART initiation, at weeks 36 and 48, sup-
pression was poorer in the youngest and older children, irrespective 
of NNRTI (global P = 0.02, P = 0.003 and P = 0.0006 for <80, 
<400 and <1000, respectively, at week 36; P = 0.09, P = 0.009 
and P = 0.03, respectively, at week 48). However, at week 144, 
older children/adolescents had poorer suppression <80 copies/
mL on efavirenz (aOR per year older = 0.79 [95% CI: 0.69–0.90] 
P < 0.001), but suppression was independent of age on nevirapine 
(aOR = 0.94 [0.79–1.11] P = 0.46) (overall effect of efavirenz vs. 
nevirapine P = 0.05; heterogeneity/interaction P = 0.09; Table 2; 
see Fig. C, Supplemental Digital Content 1, http://links.lww.com/
INF/C646). Effect sizes were similar for <400 copies/mL [efa-
virenz: aOR per year older = 0.74 (0.64–0.87) P < 0.001; nevirap-
ine: aOR = 0.88 (0.72–1.08) P = 0.23] and <1000 copies/mL [efa-
virenz: aOR = 0.72 (0.61–0.85) P < 0.001; nevirapine: aOR = 0.85 
(0.69–1.06) P = 0.14], but evidence for heterogeneity was weaker 
(P = 0.15, 0.19, respectively; Table, Supplemental Digital Con-
tent 2, http://links.lww.com/INF/C647). The relationship in those 
on efavirenz increased year-by-year across the age range with no 
TABLE 1. Characteristics of Children Receiving Efavirenz and Nevirapine at ART 
Initiation
 Efavirenz (n = 445) Nevirapine (n = 391) P*
Male 242 (54%) 176 (45%) 0.007
Age (yrs): median (IQR) 8.6 (6.4–11.0) 7.5 (4.9–10.1) <0.001
CD4 (cells/µL): median (IQR) 277 (115–436) 261 (102–476) 0.94
CD4% 12 (6–18) 10 (5–17) 0.05
Weight-for-age Z-score: median (IQR) −1.7 (−2.6 to −1.0) −2.4 (−3.6 to −1.5) <0.001
Height-for-age Z-score: median (IQR) −1.9 (−2.8 to −1.1) −2.6 (−3.5 to −1.6) <0.001
VL (copies/mL): median (IQR) 160,000 (52,000–422,000)† 199,000 (67,000–453,000)‡ 0.17
WHO stage 3/4 269 (60%) 322 (82%) <0.001
On tuberculosis treatment 43 (10%) 0 (0%) <0.001
Randomized treatment strategy 0.61
  Arm-A (3TC/ABC/NNRTI throughout) 141 (32%) 135 (35%)
  Arm-B (3TC/ABC/NNRTI throughout, 
ZDV until week 36)
153 (34%) 134 (34%)  
  Arm-C (3TC/ABC/ZDV throughout, 
NNRTI until week 36)
151 (34%) 122 (31%)  
Allocated monitoring strategy
  Routine CD4 monitoring 225 (51%) 202 (52%) 0.75
  No CD4 monitoring 220 (49%) 189 (48%)  
Country/center§   <0.001
  Uganda/Entebbe 52 (12%) 94 (24%)
  Uganda/JCRC 205 (46%) 25 (6%)  
  Uganda/PIDC 98 (22%) 45 (12%)  
  Zimbabwe/Harare 90 (20%) 227 (58%)  
*χ2 tests for categorical measures and Wilcoxon rank-sum tests for continuous measures unless otherwise indicated.
†n = 260 (185 no baseline VLs).
‡n = 235 (156 no baseline VL).
§36% received efavirenz in Entebbe, 89% in JCRC, 69% in PIDC and 28% in Harare.
JCRC indicates Joint Clinical Research Centre; PIDC, Paediatric Infectious Diseases Clinic; ZDV, zidovudine.
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evidence of nonlinearity (noting those 3–4 years of age at ART ini-
tiation were 5–9 by week 144).
Effects of other factors did not vary by NNRTI (P > 0.1 
for all thresholds). Suppression at weeks 48 and 144 was gener-
ally poorer in those reporting missing ART doses at a greater 
percentage of scheduled visits, with larger effects on the higher 
VL thresholds (<400 and <1000 copies/mL) than <80 copies/mL 
(Table, Supplemental Digital Content 2, http://links.lww.com/INF/
C647). Interestingly, at week 144, suppression was lower in lamivu-
dine + abacavir + NNRTI (Arm-A) versus lamivudine + abacavir + 
NNRTI + 36 weeks zidovudine (Arm-B) (P = 0.05).
In the subset with regular VLs, there was no evidence of 
a difference in virologic failure (≥400 copies/mL at week 24 or 
subsequent confirmed ≥400 copies/mL through 3 years) [18 of 93 
(19.4%) efavirenz vs. 8 of 52 (15.4%) nevirapine, P = 0.56 Cox 
regression adjusting for age at ART initiation and center).
DISCUSSION
WHO guidelines recommend children/adolescents ≥3 years 
initiate ART with 2 NRTI + NNRTI, where the NNRTI efavirenz is 
preferred over nevirapine. Overall, in this nonrandomized compari-
son in the ARROW trial, short-term suppression favored efavirenz, 
particularly for <80 copies/mL, but there was little difference from 
week 24 at <400 and <1000 copies/mL despite the vast majority 
remaining on the same NNRTI. Longer-term (≥48 weeks) differ-
ences were small at all thresholds, although analysis at 144 weeks 
favored efavirenz (P = 0.05). This is broadly consistent with other 
pediatric studies, which generally found efavirenz associated with 
better virologic outcome.9–11,13–16 The United Kingdom/Irish CHIPS 
study also found the most pronounced differences were shorter 
term (<2 years).
However, short-term performance of efavirenz versus nevi-
rapine also varied by pre-ART VL, with efavirenz similar at 36 and 
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FIGURE 1. Suppression (A) <80 copies/
mL over time, (B) <400 copies/mL over 
time and (C) <1000 copies/mL over time 
(only including long-term NNRTI (Arm-
A/B) from week 48 onwards).
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48 weeks regardless of pre-ART VL, but nevirapine better in those 
with lower VL (Fig. A, Supplemental Digital Content 1, http://
links.lww.com/INF/C646). Longer term (144 weeks), this was not 
apparent: suppression was independently lower in those with higher 
pre-ART VL regardless of NNRTI received and independently of 
age, potentially reflecting greater pre-ART reservoir with higher 
VL, but regardless of cause, highlights the importance of prompt 
ART initiation. The fact that the initial superiority of efavirenz at 
high pre-ART VL waned over time raises questions regarding the 
relevance of short-term suppression as an outcome, because long-
term suppression is the goal of treatment.
The other consistent predictor of suppression at every time 
point was age. Contrasting pre-ART VL, effects of age on early 
suppression occurred independently of NNRTI, with younger and 
older children having lower suppression at all thresholds, indepen-
dently of pre-ART VL and self-reported adherence. Children >10 
years were predominantly responsible for their own medication 
intake, highlighting challenges in preadolescence and adolescent 
adherence. Most children >3 years were already taking divided 
tablets, so poorer adherence with syrups is not the cause of lower 
suppression in the younger children.22 However, after 3-years 
ART, in contrast to early suppression, the relative performance of 
NNRTIs depended on age. Overall, there was at most a modest 
decline in suppression with age in children on nevirapine, con-
trasting a marked decline on efavirenz (Fig. C, Supplemental Digi-
tal Content 1, http://links.lww.com/INF/C646), the net result being 
children 10 years of age or older at ART initiation (13 years of age 
or older at VL measurement) having better long-term suppression 
with nevirapine, even after adjusting for self-reported adherence. 
One plausible explanation is the well-documented CNS side effects 
of efavirenz; preadolescents/adolescents may have taken more 
unreported treatment interruptions. Certainly, subclinical CNS 
side effects were commonly reported in adolescents in the week-
ends-off BREATHER trial23: at enrollment, adolescents reported 
CNS side effects and occasional missed doses, which they found 
difficult to report to clinic staff (S. Bernays, personal communica-
tion, May 7, 2015). Children/adolescents with CNS-related signs/
symptoms at ART initiation may have been less likely to receive 
efavirenz and simultaneously to have lower adherence. If anything, 
this would tend to favor efavirenz, particularly given necessar-
ily incomplete adjustment for self-reported adherence. It is also 
unclear whether previous studies investigated varying differences 
between efavirenz and nevirapine by age (interactions), so these 
effects may have been missed.
Interestingly, at 144 weeks, children/adolescents who had 
received an additional NRTI (zidovudine) until week 36 (Arm-B) 
had marginally better suppression than those who had not (Arm-A) 
(P = 0.05). In contrast in all children,18 including those <3 years 
of age, there was no evidence of difference [191 of 259 (73.7%) 
vs. 169 of 232 (72.8%); P = 0.82] (heterogeneity by age <3 vs. ≥3 
years at ART initiation P = 0.08). Long-term CD4 recovery was 
also greater in the induction-maintenance Arm-B.24 Long-term 
3 NRTI + NNRTI has been quite widely used (from infancy) in 
Europe,13 as this is more palatable than 3-drug lopinavir/ritonavir 
regimens and potentially more forgiving where persuading children 
to take medication is problematic.
TABLE 2. Independent Predictors of VL Suppression <80 Copies/mL at 36, 48 and 144 Weeks After 
ART Initiation
 
36 Weeks (n = 314,  
Arms A/B/C)
48 Weeks* (n = 213,  
Arms A/B)
144 Weeks* (n = 221,  
Arms A/B)
aOR (95% CI) P aOR (95% CI) P aOR (95% CI) P
VL at ART initiation
  Per log10 higher if taking efavirenz 1.01 (0.58–1.76) 0.96 0.76 (0.39–1.49) 0.42 0.59 (0.35–1.00) 0.05
  Per log10 higher if taking nevirapine 0.29 (0.15–0.56) <0.001 0.33 (0.13–0.86) 0.02
  Heterogeneity  0.003  0.15   
Efavirenz vs. nevirapine if VL 200,000  
copies/mL at ART initiation
2.55 (1.29–5.03) 0.007 0.62 (0.27–1.43) 0.27   
Efavirenz vs. nevirapine if 10 yrs of age 
at ART initiation
    1.14 (0.43–3.08) 0.79
Age at ART initiation
  Per year older if taking efavirenz     0.79 (0.69–0.90) <0.001
  Per year older if taking nevirapine     0.94 (0.79–1.11) 0.46
  Heterogeneity      0.09
Age at ART initiation vs. 5–9 yrs  0.02  0.09   
  3–4 0.73 (0.36–1.46) 0.37 0.47 (0.19–1.15) 0.10   
  10+ 0.34 (0.16–0.73) 0.006 0.38 (0.14–1.00) 0.05   
3TC/ABC/NNRTI throughout vs.  
additional 36-weeks ZDV induction*
    0.52† (0.27–1.00) 0.05
Missed any doses in last 4 weeks vs.  
not missed any doses
    0.51 (0.17–1.52) 0.23
% visits to date with missed doses in  
last 4 weeks (per 10% higher)
  0.76 (0.57–1.00) 0.05 0.84 (0.59–1.21) 0.36
Center vs. A  0.47‡     
  B 1.00 (0.45–2.25) 0.99     
  C 0.58 (0.28–1.23) 0.16     
  D 0.69 (0.31–1.49) 0.34     
Overall efavirenz vs. nevirapine  
(incorporating interaction effects above)
 0.0004  0.26  0.05
*Only including children receiving long-term NNRTIs (Arm A/B) in analyses from week 48 onwards
†There was no evidence of interaction between NNRTI and allocated ART strategy (P > 0.1).
‡Included because significant variation in suppression <400 copies/mL and <1000 copies/mL by center at week 36 (Table, Supplemental Digital 
Content 2, http://links.lww.com/INF/C647).
n indicates complete cases.
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Our results confirm the generally favorable toxicity profile 
of both nevirapine and efavirenz, with only 8 nevirapine and 2 efa-
virenz hypersensitivity reactions, and ~2% permanently discon-
tinuing each NNRTI because of any AE, in a clinical setting where 
clinicians may not discontinue a drug despite toxicity if the toxicity 
is not life-threatening. Gynecomastia resulted in permanent discon-
tinuation of efavirenz in 2 children, 1% of those receiving it long 
term. Permanent discontinuations for non-AE reasons were more 
frequent with nevirapine, particularly tuberculosis treatment, which 
is an advantage of efavirenz in children at high risk of tuberculosis 
shortly after ART initiation.25 No switches to second-line treatment 
occurred before 48 weeks with either regimen.
Although children were not randomized to nevirapine or 
efavirenz, potential confounders were considered for inclusion 
in models; nonetheless, there is always the possibility of residual 
confounding. A major limitation of our study is incomplete VL 
sampling: however, assays were performed to answer questions not 
depending on receipt of nevirapine or efavirenz, so will not bias 
this comparison. Although sampling was incomplete, restricting 
power for interactions particularly, our study is of similar size to 
others (with 4-year follow-up); the suggestion that older children 
had better long-term suppression with nevirapine requires further 
study. All children received the WHO-recommended backbone 
NRTIs lamivudine + abacavir.6 Although approximately one-third 
also received zidovudine until week 36, this did not affect rela-
tive performance of efavirenz versus nevirapine; other regimens 
are unlikely to have altered relative impact of different NNRTIs. 
We considered 3 thresholds for suppression (<80, <400 and <1000 
copies/mL); while <80 copies/mL provides a sensitive investigation 
of impact of low-level resistant variants, <400 and <1000 copies/
mL may be more relevant in clinical practice, particularly resource-
limited settings. Results were generally similar over thresholds. 
We prespecified an exit P value of 0.1 for backwards selection to 
develop an explanatory model; however, this increases the chance 
of type I error (false positives).
In summary, we confirm results from other pediatric stud-
ies that efavirenz is associated with better initial virologic outcome 
than nevirapine, particularly at higher pre-ART VLs, but longer 
term, we found they are broadly similar, with nevirapine even hav-
ing some advantage in older children. This supports the 2013 WHO 
recommendation that nevirapine should continue as a reasonable 
alternative to efavirenz, particularly in older children/adolescents. 
It also suggests there is no particular reason to substitute nevirap-
ine in children doing well on first-line ART. Both nevirapine and 
efavirenz have generally favorable toxicity profiles, although cli-
nicians need to remain alert to the possibility of hypersensitivity 
reactions with either.
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